John H. Johnson
Interim Chief Executive Officer and Director
Mr. Johnson serves as interim chief executive officer of Melinta and has served on Melinta’s board of directors since the recent merger with Cempra. He previously served as a member of Cempra’s board of directors from June 2009 until the company’s merger with Melinta, and as a director at Sucampo. Mr. Johnson served as president and chief executive officer of Dendreon Corporation, a publicly traded biotechnology company (NASDAQ: DNDN), from February 2012, became chairman in July 2013, and served as chairman until June 2014 and president and chief executive officer until August 2014. Mr. Johnson was senior vice president of Eli Lilly (NYSE: LLY) and Company and president of Lilly Oncology, Eli Lilly’s oncology business unit, from 2009 to 2011. From 2007 to 2009, Mr. Johnson was chief executive officer of ImClone Systems Incorporated, a biopharmaceutical development company, and was also a member of ImClone’s board of directors until it became a wholly owned subsidiary of Eli Lilly in 2008. From 2005 to 2007, Mr. Johnson served as the company group chairman of biopharmaceuticals within Johnson & Johnson, where he was responsible for biotechnology, immunology and oncology commercial business units. Mr. Johnson served as chairman of the board of Tranzyme, Inc. (NASDAQ: TZYM), a publicly traded biopharmaceutical company, from December 2010 until July 2013. Prior to that role, he held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corporation and Pfizer Inc. While at Ortho-McNeil, Mr. Johnson was responsible for the company’s anti-infectives portfolio. Mr. Johnson currently serves as the chairman of the board of Strongbridge Biopharma plc (NASDAQ: SBBP), and also serves as a director of Aveo Oncology (NASDAQ: AVEO), Histogenics Corporation (NASDAQ: HSGX), and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). During his career, Mr. Johnson also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ. Mr. Johnson holds a B.S. in Education from East Stroudsburg University of Pennsylvania. Among other experience, qualifications, attributes and skills, Mr. Johnson’s extensive leadership experience and commercial expertise with biopharmaceutical organizations quality him to serve on our board of directors.